Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 6:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 4,216 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Injectable Placebo Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Immunogenicity of an HIV Vaccine (gp145 C.6980) in Healthy, HIV-Uninfected Adults in the United States

NCT03382418
View directory record Official record
Conditions
HIV Infections
Interventions
gp145 C.6980 Vaccine, Placebo, Aluminum Hydroxide Adjuvant
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
3
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 8, 2021 · Synced Oct 27, 2026, 6:06 PM EDT
Terminated Phase 1Phase 2 Interventional

Mesenchymal Stem Cells for the Treatment of Rectovaginal Fistulas in Participants With Crohn's Disease

NCT04519697
View directory record Official record
Conditions
Rectovaginal Fistula, Crohn Disease, Crohn Disease of Vulva, Rectolabial; Fistula
Interventions
Mesenchymal Stem Cells, Placebo
Drug · Other
Lead sponsor
Anthony Lembo
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 27, 2026, 6:06 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin

NCT00099320
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
21 Years to 75 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
40
States / cities
Birmingham, Alabama • La Jolla, California • San Mateo, California + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Oct 27, 2026, 6:06 PM EDT
Completed Phase 2Phase 3 Interventional

Micronized dHACM Injectable for the Treatment of Plantar Fasciitis

NCT02427191
View directory record Official record
Conditions
Fasciitis, Plantar
Interventions
AmnioFix® Injectable, Saline Injection
Other · Drug
Lead sponsor
MiMedx Group, Inc.
Industry
Eligibility
21 Years to 79 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
11
States / cities
Tucson, Arizona • Fresno, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 27, 2026, 6:06 PM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Efficacy and Safety of NT 201 (Botulinum Toxin) Compared With Placebo for the Treatment of Adult Participants With Essential Tremor in the Arm

NCT04766723
View directory record Official record
Conditions
Essential Tremor of the Upper Limb
Interventions
NT 201, Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
9
States / cities
Tampa, Florida • Omaha, Nebraska • Las Vegas, Nevada + 6 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 27, 2026, 6:06 PM EDT
Completed Phase 4 Interventional Results available

Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia

NCT00690235
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Diabetes, Weight Gain
Interventions
Pramlintide, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 27, 2026, 6:06 PM EDT
Completed Phase 3 Interventional Results available

Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis

NCT02404350
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Secukinumab
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
997 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
22
States / cities
Upland, California • Aurora, Colorado • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Oct 27, 2026, 6:06 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Restylane Silk for Treatment of Chest Wrinkles

NCT03324997
View directory record Official record
Conditions
Wrinkle
Interventions
Restylane Silk, Saline, Optical Coherence Tomography
Drug · Device
Lead sponsor
Heidi Waldorf
Other
Eligibility
25 Years to 55 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced Oct 27, 2026, 6:06 PM EDT
Completed Phase 3 Interventional Results available

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

NCT01144338
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Exenatide Once Weekly, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
14,752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
139
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 124 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Oct 27, 2026, 6:06 PM EDT
Completed Phase 2 Interventional Results available

Study of the Safety and Efficacy of REGN727/SAR236553 in Patients With HeFH Hypercholesterolemia

NCT01266876
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
17
States / cities
Huntsville, Alabama • Mission Viejo, California • Newport Beach, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2015 · Synced Oct 27, 2026, 6:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of Growth Hormone and Bone in Obesity

NCT01724489
View directory record Official record
Conditions
Obesity, Osteopenia
Interventions
Growth hormone, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 27, 2026, 6:06 PM EDT
Terminated Phase 2 Interventional

Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19

NCT04389450
View directory record Official record
Conditions
COVID, ARDS
Interventions
PLX-PAD, Placebo
Biological
Lead sponsor
Pluristem Ltd.
Industry
Eligibility
40 Years to 80 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
13
States / cities
Irvine, California • Los Angeles, California • Sacramento, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2024 · Synced Oct 27, 2026, 6:06 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway

NCT05194124
View directory record Official record
Conditions
Bardet-Biedl Syndrome, POMC Deficiency
Interventions
Setmelanotide 2 mg, Setmelanotide 2.5 mg, Setmelanotide 3 mg, Setmelanotide 20 mg, Setmelanotide 25 mg, Setmelanotide 30 mg
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
6 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Scottsdale, Arizona • Marshfield, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 27, 2026, 6:06 PM EDT
Completed Phase 3 Interventional

A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

NCT06065540
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
2,734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
100
States / cities
Birmingham, Alabama • Pelham, Alabama • Phoenix, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 27, 2026, 6:06 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC35 Injection in Participants With Obesity or Overweight

NCT07842640
View directory record Official record
Conditions
Chronic Weight Management
Interventions
ASC35 Injection B, for subcutaneous use, ASC35 Placebo Injection B, for subcutaneous use, Tirzepatide
Drug
Lead sponsor
Ascletis Pharma (China) Co., Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 27, 2026, 6:06 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study To Assess The Safety And Tolerability Of Increasing Single Doses Of ATR-107 (PF-05230900) In Healthy People

NCT01162889
View directory record Official record
Conditions
Healthy
Interventions
Placebo SC Injection, ATR-107 (PF-05230900) SC Injection, ATR-107 (PF-05230900) IV Infusion, Placebo IV Infusion
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
2
States / cities
New Haven, Connecticut • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 27, 2026, 6:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad35.RSV.FA2 Regimens Boosted With Ad26.RSV.FA2 in Healthy Adult Participants

NCT02440035
View directory record Official record
Conditions
Healthy Participants
Interventions
Ad35.RSV.FA2, Ad26.RSV.FA2, Placebo
Biological · Drug
Lead sponsor
Crucell Holland BV
Industry
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Oct 27, 2026, 6:06 PM EDT
Withdrawn Phase 1 Interventional

Exenatide For Reducing the Reinforcing Effects of Cocaine

NCT06252623
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Exenatide, Placebo
Drug
Lead sponsor
Christopher D. Verrico
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 27, 2026, 6:06 PM EDT
Completed Phase 3 Interventional Results available

A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)

NCT04896008
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Sotatercept, Placebo
Drug · Other
Lead sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Industry
Eligibility
18 Years to 75 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
26
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 27, 2026, 6:06 PM EDT
Not listed Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure.

NCT01643590
View directory record Official record
Conditions
Ischemic Heart Failure
Interventions
JVS-100 15 mg dose Injection, Placebo Injection, JVS-100 30 mg dose injection
Biological
Lead sponsor
Juventas Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
16
States / cities
Birmingham, Alabama • Gainesville, Florida • Tampa, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2014 · Synced Oct 27, 2026, 6:06 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Dosing of AMG 827 for Subjects With Inadequately Controlled Asthma

NCT01199289
View directory record Official record
Conditions
Asthma
Interventions
AMG 827, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
22
States / cities
Encinitas, California • Huntington Beach, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2021 · Synced Oct 27, 2026, 6:06 PM EDT
Recruiting Phase 3 Interventional

A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

NCT07221188
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease
Interventions
Efimosfermin Alfa, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
57
States / cities
Arcadia, California • Covina, California • Los Angeles, California + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 27, 2026, 6:06 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study Involving SAB01 and Healthy Participants

NCT07815561
View directory record Official record
Conditions
Healthy Adult Participants
Interventions
Subcutaneous (SC) single dose of SAB01, Intravenous (IV) infusion of SAB01, Placebo SC, Placebo IV Infusion
Drug
Lead sponsor
Santa Ana Bio
Industry
Eligibility
18 Years to 55 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 27, 2026, 6:06 PM EDT
Withdrawn Phase 3 Interventional

Calprotectin-Directed Humira® Maintenance Therapy (CADHUM)

NCT01674413
View directory record Official record
Conditions
Crohn's Disease
Interventions
Adalimumab, Adalimumab PRN, Placebo
Drug
Lead sponsor
Peter Higgins
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 24, 2017 · Synced Oct 27, 2026, 6:06 PM EDT